Recce Ltd has released a press release.
Opening R&D Address at World AMR Congress
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- RECCE Trademark Registered - Vietnam
- Additional Positive Patient Cases - Special Access Scheme
- Appendix 4E and Unaudited Preliminary Report
- Next Dose Cleared in Rapid Infusion Phase I/II UTI Trial
- Patients Dosed in R327 Diabetic Foot Infection Trial
Later from Recce Pharmaceuticals
- Placement and Entitlement Offer
- Completes Cohort Dosing UTI/Urosepsis Rapid Infusion Trial
- Committee Approves Fast 15-Min Infusion in Ph I/II Urosepsis
- Subjects Dosed Over 15 mins in UTI/Urosepsis Clinical Trial
- Canadian Patent Granted for RECCE Anti-Infectives
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals